Lucence Diagnostics participated in the American Society of Clinical Oncology (ASCO) Annual Meeting held on June 1-3, 2019 in Chicago. It is the world’s largest cancer conference with 40,000 oncologists gathered across the globe to learn the latest cancer developments. ASCO marks our first technology showcase outside Asia.
We showcased our flagship liquid biopsy test LiquidHALLMARK™, which is now available in the United States. It is the world’s first liquid biopsy test that detects cancer-causing mutations and viruses in 14 different cancers. This test is based on our proprietary amplicon-based ultra-deep sequencing technology AmpliMARK™ for maximizing sensitivity, which is crucial for accurate detection and monitoring of cancer.
We also released a white paper on “Liquid Biopsies for Lung Cancer: Vision 2020’’. Our CEO and Medical Director, Dr Min-Han Tan, and our CTO, Dr Yukti Choudhury, share their expert perspectives on the current state and future expectations for liquid biopsies in lung cancer in this white paper. Download a copy of the white paper.
Lucence looks forward to working with healthcare providers in the United States to deliver our liquid biopsy technology.
Dr Min-Han Tan with Dr Elad Sharon (U.S. National Cancer Institute) and Dr Kevin Tay (Oncocare Cancer Centre).
From left: Dr Tan Yew Oo (IconSOC), Dr Min-Han Tan, Dr Soe Aung (Yangon General Hospital, Myanmar) and Dr Jens Samol (Tan Tock Seng Hospital).
Dr Janice Tsang from Queen Mary Hospital, Hong Kong (second from left) with Mr Jamen Loh, Dr Min-Han Tan, Ms Aster Ding and Dr Jack Challis from Lucence Diagnostics (from right).